β-lactam activity against penicillin-resistant Streptococcus pneumoniae strains exhibiting higher amoxicillin versus penicillin minimum inhibitory concentration values:: An in vitro pharmacodynamic simulation

被引:6
作者
Sevillano, D. [1 ]
Aguilar, L. [1 ]
Alou, L. [1 ]
Gimenez, M. J. [1 ]
Gonzalez, N. [1 ]
Echeverria, O. [1 ]
Torrico, M. [1 ]
Valdes, L. [2 ]
Coronel, P. [3 ]
Prieto, J. [1 ]
机构
[1] Univ Complutense, Dept Microbiol, Sch Med, ES-28040 Madrid, Spain
[2] GlaxoSmithKline SA, Dept Med, Madrid, Spain
[3] Tedec Meiji Farma SA, Dept Sci, Madrid, Spain
关键词
pharmacodynamic simulation; Streptococcus pneumoniae; amoxicillin resistance; bactericidal activity; cefditoren; cefuroxime; amoxicillin/clavulanic acid;
D O I
10.1159/000118659
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Activity of simulated serum concentrations after oral therapy with 400 mg cefditoren pivoxil b.i.d., 500 mg cefuroxime axetil b.i.d. and 875/125 mg amoxicillin/clavulanic acid b.i.d. and t.i.d. regimens was explored over 24 h against Streptococcus pneumoniae. Methods: Computerized pharmacodynamic simulations were performed against strains with penicillin/amoxicillin/cefuroxime/cefditoren minimum inhibitory concentrations (MICs, mu g/ml) and serotypes: strain 1 (0.25/0.12/1/0.12; serotype 6A), strain 2 (2/4/2/0.25; serotype 6B), strain 3 (4/16/4/0.5; serotype 14), and strain 4 (4/16/8/1; serotype 14). Results: Bactericidal activity (6 3 log 10 reduction) at 12 and 24 h was obtained against all strains with cefditoren, against strains 1 and 2 with cefuroxime and amoxicillin/clavulanic acid t.i.d., but only against strain 1 with amoxicillin/clavulanic acid b.i.d.. Bactericidal activity at 24 h was related to T > MIC of >30% dosing interval, 1.7-2.0 log(10) reductions with T > MIC of 20-30%, and <1 log(10) reduction or regrowth with T > MIC of 0%. Conclusions: It is difficult to achieve pharmacodynamic coverage and bactericidal activity by physiological concentrations of oral beta-lactams against penicillin-resistant pneumococcal strains exhibiting higher amoxicillin versus penicillin MICs. Cefditoren may offer alternatives. Copyright (c) 2008 S. Karger AG, Basel.
引用
收藏
页码:84 / 90
页数:7
相关论文
共 21 条
[1]  
ANDREWS JM, 1999, CLIN ANTIMICROBIAL A
[2]  
[Anonymous], [No title captured]
[3]   Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers [J].
Burkhardt, O ;
Borner, K ;
von der Höh, N ;
Köppe, P ;
Pletz, MW ;
Nord, CE ;
Lode, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (05) :707-712
[4]   Very high resistance to amoxicillin in Streptococcus pneumoniae:: an epidemiological fact or a technical issue? [J].
Camacho, M. -T. ;
Casal, J. ;
Aguilar, L. ;
Giménez, M. -J. ;
Fenoll, A. .
JOURNAL OF CHEMOTHERAPY, 2006, 18 (03) :303-306
[5]   Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States [J].
Doern, GV .
CLINICAL INFECTIOUS DISEASES, 2001, 33 :S187-S192
[6]   Activity of cefditoren against clinical isolates of Streptococcus pneumoniae showing non-susceptibility to penicillins, cephalosporins, macrolides, ketolides or quinolones [J].
Fenoll, Asuncion ;
Gimenez, Maria-Jose ;
Robledo, Olga ;
Coronel, Pilar ;
Gimeno, Mercedes ;
Casal, Julio ;
Aguilar, Lorenzo .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 (02) :224-226
[7]   PHARMACOKINETICS AND URINARY-EXCRETION OF CLAVULANIC ACID AFTER ORAL-ADMINISTRATION OF AMOXICILLIN AND POTASSIUM CLAVULANATE [J].
FERSLEW, KE ;
DAIGNEAULT, EA ;
ATEN, EM ;
ROSEMAN, JM .
JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 24 (10) :452-456
[8]   EFFECT OF DOSE AND FOOD ON THE BIOAVAILABILITY OF CEFUROXIME AXETIL [J].
FINN, A ;
STRAUGHN, A ;
MEYER, M ;
CHUBB, J .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1987, 8 (06) :519-526
[9]   PHARMACOKINETICS AND TISSUE DISTRIBUTION OF AMOXICILLIN PLUS CLAVULANIC ACID AFTER ORAL-ADMINISTRATION IN MAN [J].
FRASCHINI, F ;
SCAGLIONE, F ;
FALCHI, M ;
DUGNANI, S ;
MEZZETTI, M ;
CICCHETTI, F ;
ALFANO, G ;
PINTUCCI, GP .
JOURNAL OF CHEMOTHERAPY, 1990, 2 (03) :171-177
[10]   Management of clinical failures in non-ICU patients with chronic obstructive pulmonary disease exacerbations [J].
Habib, MP .
CHEMOTHERAPY, 2001, 47 :39-46